Genmab A/S (GNMSF) News Today → The only financial event in 2024 that matters (From Porter & Company) (Ad) Free GNMSF Stock Alerts $275.67 -8.61 (-3.03%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 25, 2024 | americanbankingnews.comGenmab A/S (OTCMKTS:GNMSF) Shares Pass Below 200 Day Moving Average of $297.44May 20, 2024 | markets.businessinsider.comGenmab’s Buy Rating Affirmed by Promising Epcoritamab Trials and Regulatory MilestonesMay 20, 2024 | markets.businessinsider.comWhat 9 Analyst Ratings Have To Say About GenmabMay 14, 2024 | finance.yahoo.comDanish biotech says companies should tap into China’s ‘impressive innovation’May 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Genmab on Strong TIVDAK Approval and Promising Pipeline ValuationMay 1, 2024 | finance.yahoo.comComstock Inc (LODE) Q1 2024 Earnings Call Transcript Highlights: Strategic Investments and ...April 16, 2024 | seekingalpha.comGenmab Acquires A Missing Piece For Its PipelineApril 16, 2024 | markets.businessinsider.comGenmab's Q1 Darzalex Sales By Johnson & Johnson Reach $2.692 BlnApril 9, 2024 | markets.businessinsider.comTruist Financial Keeps Their Buy Rating on Genmab (GMAB)April 8, 2024 | benzinga.comProfoundBio discovers the joys of having a wealthy ownerMarch 17, 2024 | finance.yahoo.com30 Biggest Biotechnology Companies in the WorldMarch 13, 2024 | finance.yahoo.comPassing of Genmab A/S’ Annual General MeetingFebruary 21, 2024 | seekingalpha.comGenmab: Recent Updates Support The Growth NarrativeFebruary 20, 2024 | markets.businessinsider.com4 Analysts Assess Genmab: What You Need To KnowFebruary 15, 2024 | msn.comGenmab A/S’ New Regulation Risk – A Cause for Worry?February 15, 2024 | finance.yahoo.comGenmab A/S (NASDAQ:GMAB) Q4 2023 Earnings Call TranscriptFebruary 15, 2024 | finance.yahoo.comNotice to Convene the Annual General Meeting of Genmab A/SFebruary 14, 2024 | finance.yahoo.comGenmab Files Annual Report with the U.S. Securities and Exchange CommissionFebruary 14, 2024 | finance.yahoo.comGenmab: Growth Is Still a Better ChoiceFebruary 2, 2024 | finance.yahoo.comTisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical CancerJanuary 29, 2024 | markets.businessinsider.comCracking The Code: Understanding Analyst Reviews For GenmabJanuary 25, 2024 | finance.yahoo.comGrant of Restricted Stock Units and Warrants to Employees in GenmabJanuary 22, 2024 | finance.yahoo.comGenmab Announces Decision in Arbitration Appeal under License Agreement with JanssenDecember 7, 2023 | finance.yahoo.comHRMY or GMAB: Which Is the Better Value Stock Right Now?November 8, 2023 | finance.yahoo.comGenmab A/S (NASDAQ:GMAB) Q3 2023 Earnings Call TranscriptNovember 7, 2023 | msn.comGenmab reports 9M resultsNovember 7, 2023 | finance.yahoo.comGenmab Announces Financial Results for the First Nine Months of 2023November 2, 2023 | finance.yahoo.comGenmab Announces Multiple Abstracts to be Presented at the 65th Annual Meeting and Exposition of the American Society of Hematology (ASH)October 23, 2023 | msn.comGenmab and Seagen report positive data from Phase III TIVDAK trialOctober 23, 2023 | msn.comSeagen, Genmab update Phase 3 data for uterine cancer therapyOctober 17, 2023 | finance.yahoo.comGenmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2023October 13, 2023 | benzinga.comWhat 13 Analyst Ratings Have To Say About GenmabSeptember 28, 2023 | finance.yahoo.comDiversified Stock Portfolio: 10 Sector ETFs and International ETFs to BuySeptember 25, 2023 | finance.yahoo.comEPKINLYTM (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare as the First Bispecific Antibody to Treat Adults Patients with Certain Types of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)September 25, 2023 | finance.yahoo.comEPKINLY™ (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare as the First Bispecific Antibody to Treat Adults Patients with Certain Types of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)September 25, 2023 | finance.yahoo.comGenmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)September 4, 2023 | markets.businessinsider.comGenmab : Phase 3 Trial Of TIVDAK In Recurrent Or Metastatic Cervical Cancer Meets Primary EndpointSeptember 4, 2023 | finance.yahoo.comSeagen and Genmab Announce TIVDAK® (tisotumab vedotin-tftv) Improved Overall Survival in Patients With Recurrent or Metastatic Cervical Cancer Compared With Chemotherapy AloneSeptember 4, 2023 | finance.yahoo.comGenmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to ChemotherapySeptember 4, 2023 | finance.yahoo.comUPDATE 1-Genmab, Seagen say Tivdak cervical cancer trial met overall survival endpointAugust 28, 2023 | finance.yahoo.comGenmab to Present at Morgan Stanley 21st Annual Global Healthcare ConferenceAugust 3, 2023 | finance.yahoo.comGenmab Announces Financial Results for the First Half of 2023July 28, 2023 | finance.yahoo.comGenmab Updates 2023 Financial GuidanceJuly 2, 2023 | finance.yahoo.comCould This New Drug Be a Blockbuster for These 2 Pharma Collaborators?June 27, 2023 | finance.yahoo.comGenmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)June 22, 2023 | finance.yahoo.comGenmab Announces Epcoritamab Added to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for ‘B-Cell Lymphomas’June 9, 2023 | finance.yahoo.comGenmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas at European Hematology Association (EHA) Annual Meeting 2023June 6, 2023 | benzinga.comExpert Ratings for GenmabJune 6, 2023 | finance.yahoo.comGenmab to Participate in a Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare ConferenceMay 19, 2023 | finance.yahoo.comEPKINLY™ (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Get Genmab A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for GNMSF and its competitors with MarketBeat's FREE daily newsletter. Email Address The only financial event in 2024 that matters (Ad)Man Who Predicted 2008 Crash Warns of Black Swan Financial Event in 2024 Porter Stansberry’s new documentary is going viral. Stream the documentary for free by clicking here GNMSF Media Mentions By Week GNMSF Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GNMSF News Sentiment▼1.000.76▲Average Medical News Sentiment GNMSF News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GNMSF Articles This Week▼10▲GNMSF Articles Average Week Get Genmab A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for GNMSF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Bayer Aktiengesellschaft News Today Capstone News Today EOM Pharmaceuticals News Today Grifols News Today Hypera News Today IMV News Today International Stem Cell News Today Mainz Biomed News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:GNMSF) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaBiden Nomination CANCELED?The Freeport SocietyExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsElon to Transform U.S. Economy? Porter & CompanyBiden replacement revealed?Paradigm PressThis unknown company solves the biggest issue with AIManward Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genmab A/S Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
